Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%
Status:
Terminated
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
Randomized, double-blind, parallel group, placebo-controlled, multicenter, efficacy and
safety study in subjects with mild to moderate atopic dermatitis.
Following the double blind period, subjects will be allowed to continue treatment with
topical MRX-6 Cream 2% in an open-label extension. Demonstrate the efficacy of MRX-6 Cream 2%
compared to Vehicle for the treatment of the signs and symptoms of atopic dermatitis and
demonstrate the safety of MRX-6 Cream 2% for the treatment of the signs and symptoms of
atopic dermatitis.